Mechanisms of Subcutaneous Allergen Immunotherapy

Immunology and Allergy Clinics of North America

Volumn 31, Issue 2, 2011, Pages 175-190

  Soyer, Ozge U ^a   Akdis, Mubeccel ^b   Akdis, Cezmi A ^b  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Allergen immunotherapy; Allergy; Immune tolerance; Interleukin 10; T regulatory cells; Transforming growth factor

Indexed keywords

ALLERGEN; BEE VENOM; FC RECEPTOR; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGIC ASTHMA; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN PRESENTING CELL; ASTHMA; ATOPIC DERMATITIS; B LYMPHOCYTE; BASOPHIL; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; COMPLEMENT ACTIVATION; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SENSITIZATION; DRUG SPECIFICITY; EFFECTOR CELL; EOSINOPHIL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LOW DRUG DOSE; MAST CELL; MILK ALLERGY; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL; TREATMENT DURATION;

ADMINISTRATION, CUTANEOUS; ALLERGENS; ANTIBODIES; ANTIBODY SPECIFICITY; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; IMMUNE TOLERANCE; INTERLEUKIN-10; T-LYMPHOCYTES, REGULATORY;

EID: 79955438078     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2011.02.006     Document Type: Review

References (130)

1. Galli S.J., Tsai M., Piliponsky A.M. The development of allergic inflammation. Nature 2008, 454(7203):445-454.
2. Larche M., Akdis C.A., Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006, 6(10):761-771.
3. Akdis M., Akdis C.A. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2007, 119(4):780-791.
4. Jutel M., Akdis M., Akdis C.A. Histamine, histamine receptors and their role in immune pathology. Clin Exp Allergy 2009, 39(12):1786-1800.
5. Akdis C.A., Jutel M., Akdis M. Regulatory effects of histamine and histamine receptor expression in human allergic immune responses. Chem Immunol Allergy 2008, 94:67-82.
6. Akdis M., Burgler S., Crameri R., et al. Interleukins from 1 to 37 and interferon-gamma. J Allergy Clin Immunol 2011, 127:701-721. e70.
7. Robinson D.S., Larche M., Durham S.R. Tregs and allergic disease. J Clin Invest 2004, 114(10):1389-1397.
8. Akdis C.A. Allergy and hypersensitivity: mechanisms of allergic disease. Curr Opin Immunol 2006, 18(6):718-726.
9. Akdis M., Verhagen J., Taylor A., et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004, 199(11):1567-1575.
10. Louten J., Boniface K., de Waal Malefyt R. Development and function of TH17 cells in health and disease. J Allergy Clin Immunol 2009, 123(5):1004-1011.
11. Akdis M. The cellular orchestra in skin allergy; are differences to lung and nose relevant?. Curr Opin Allergy Clin Immunol 2010, 10(5):443-451.
12. Burgler S., Ouaked N., Bassin C., et al. Differentiation and functional analysis of human T(H)17 cells. J Allergy Clin Immunol 2009, 123(3):588-595. e581-7.
13. Akdis C.A. T cells in health and disease. J Allergy Clin Immunol 2009, 123(5):1022-1023.
14. Bousquet J., Bachert C., Canonica G.W., et al. Unmet needs in severe chronic upper airway disease (SCUAD). J Allergy Clin Immunol 2009, 124(3):428-433.
15. Zielen S., Kardos P., Madonini E. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. J Allergy Clin Immunol 2010, 126(5):942-949.
16. Palomares O., Yaman G., Azkur A.K., et al. Role of Treg in immune regulation of allergic diseases. Eur J Immunol 2010, 40(5):1232-1240.
17. Akdis M., Akdis C.A. Therapeutic manipulation of immune tolerance in allergic disease. Nat Rev Drug Discov 2009, 8(8):645-660.
18. Akdis C.A., Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2011, 127:18-27.
19. Akdis M. Immune tolerance in allergy. Curr Opin Immunol 2009, 21(6):700-707.
20. Ozdemir C., Akdis M., Akdis C.A. T regulatory cells and their counterparts: masters of immune regulation. Clin Exp Allergy 2009, 39(5):626-639.
21. Akdis C.A. New insights into mechanisms of immunoregulation in 2007. J Allergy Clin Immunol 2008, 122(4):700-709.
22. Jutel M., Akdis M., Budak F., et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003, 33(5):1205-1214.
23. Meiler F., Zumkehr J., Klunker S., et al. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008, 205(12):2887-2898.
24. Ling E.M., Smith T., Nguyen X.D., et al. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004, 363(9409):608-615.
25. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299(5609):1057-1061.
26. Bennett C.L., Christie J., Ramsdell F., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001, 27(1):20-21.
27. Siegmund K., Ruckert B., Ouaked N., et al. Unique phenotype of human tonsillar and in vitro-induced FOXP3+CD8+ T cells. J Immunol 2009, 182(4):2124-2130.
28. Wildin R.S., Smyk-Pearson S., Filipovich A.H. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 2002, 39(8):537-545.
29. Gambineri E., Perroni L., Passerini L., et al. Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: inconsistent correlation between Forkhead box protein 3 expression and disease severity. J Allergy Clin Immunol 2008, 122(6):1105-1112. e1.
30. Akdis C.A., Akdis M. Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. J Allergy Clin Immunol 2009, 123(4):735-746. [quiz: 747-8].
31. Verhagen J., Akdis M., Traidl-Hoffmann C., et al. Absence of T-regulatory cell expression and function in atopic dermatitis skin. J Allergy Clin Immunol 2006, 117(1):176-183.
32. Ito Y., Adachi Y., Makino T., et al. Expansion of FOXP3-positive CD4+CD25+ T cells associated with disease activity in atopic dermatitis. Ann Allergy Asthma Immunol 2009, 103(2):160-165.
33. Zimmermann M., Koreck A., Meyer N., et al. TWEAK and TNF-alpha cooperate in the induction of keratinocyte apoptosis. J Allergy Clin Immunol 2011, 127:200-207. e1-10.
34. Smyth L.J., Eustace A., Kolsum U., et al. Increased airway T regulatory cells in asthmatic subjects. Chest 2010, 138(4):905-912.
35. Karagiannidis C., Akdis M., Holopainen P., et al. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol 2004, 114(6):1425-1433.
36. Anderson A.E., Mackerness K.J., Aizen M., et al. Seasonal changes in suppressive capacity of CD4+ CD25+ T cells from patients with hayfever are allergen-specific and may result in part from expansion of effector T cells among the CD25+ population. Clin Exp Allergy 2009, 39(11):1693-1699.
37. Leech M.D., Benson R.A., De Vries A., et al. Resolution of Der p1-induced allergic airway inflammation is dependent on CD4+CD25+Foxp3+ regulatory cells. J Immunol 2007, 179(10):7050-7058.
38. Jones T.G., Finkelman F.D., Austen K.F., et al. T regulatory cells control antigen-induced recruitment of mast cell progenitors to the lungs of C57BL/6 mice. J Immunol 2010, 185(3):1804-1811.
39. Reefer A.J., Satinover S.M., Solga M.D., et al. Analysis of CD25hiCD4+ "regulatory" T-cell subtypes in atopic dermatitis reveals a novel T(H)2-like population. J Allergy Clin Immunol 2008, 121(2):415-422. e3.
40. Jartti T., Burmeister K.A., Seroogy C.M., et al. Association between CD4(+)CD25(high) T cells and atopy in children. J Allergy Clin Immunol 2007, 120(1):177-183.
41. Mamessier E., Nieves A., Lorec A.M., et al. T-cell activation during exacerbations: a longitudinal study in refractory asthma. Allergy 2008, 63(9):1202-1210.
42. Maggi L., Santarlasci V., Liotta F., et al. Demonstration of circulating allergen-specific CD4+CD25highFoxp3+ T-regulatory cells in both nonatopic and atopic individuals. J Allergy Clin Immunol 2007, 120(2):429-436.
43. Nguyen K.D., Vanichsarn C., Nadeau K.C. Increased cytotoxicity of CD4+ invariant NKT cells against CD4+CD25hiCD127lo/- regulatory T cells in allergic asthma. Eur J Immunol 2008, 38(7):2034-2045.
44. Bellinghausen I., Konig B., Bottcher I., et al. Regulatory activity of human CD4 CD25 T cells depends on allergen concentration, type of allergen and atopy status of the donor. Immunology 2005, 116(1):103-111.
45. Karlsson M.R., Rugtveit J., Brandtzaeg P. Allergen-responsive CD4+CD25+ regulatory T cells in children who have outgrown cow's milk allergy. J Exp Med 2004, 199(12):1679-1688.
46. Han D., Wang C., Lou W., et al. Allergen-specific IL-10-secreting type I T regulatory cells, but not CD4(+)CD25(+)Foxp3(+) T cells, are decreased in peripheral blood of patients with persistent allergic rhinitis. Clin Immunol 2010, 136(2):292-301.
47. McGee H.S., Agrawal D.K. Naturally occurring and inducible T-regulatory cells modulating immune response in allergic asthma. Am J Respir Crit Care Med 2009, 180(3):211-225.
48. O'Garra A., Barrat F.J., Castro A.G., et al. Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev 2008, 223:114-131.
49. Akdis C.A., Blesken T., Akdis M., et al. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998, 102(1):98-106.
50. Ozdemir C., Akdis M., Akdis C.A. Nature of regulatory T cells in the context of allergic disease. Allergy Asthma Clin Immunol 2008, 4(3):106-110.
51. Kearley J., Barker J.E., Robinson D.S., et al. Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4+CD25+ regulatory T cells is interleukin 10 dependent. J Exp Med 2005, 202(11):1539-1547.
52. De Waal Malefyt R., Abrams J., Bennett B., et al. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991, 174:1209-1220.
53. Taylor A., Akdis M., Joss A., et al. IL-10 inhibits CD28 and ICOS costimulations of T cells via src homology 2 domain-containing protein tyrosine phosphatase 1. J Allergy Clin Immunol 2007, 120(1):76-83.
54. Le T., Tversky J., Chichester K.L., et al. Interferons modulate Fc epsilon RI-dependent production of autoregulatory IL-10 by circulating human monocytoid dendritic cells. J Allergy Clin Immunol 2009, 123(1):217-223.
55. Amu S., Saunders S.P., Kronenberg M., et al. Regulatory B cells prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in a murine model. J Allergy Clin Immunol 2010, 125(5):1114-1124. e1118.
56. Gregori S., Tomasoni D., Pacciani V., et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood 2010, 116(6):935-944.
57. Cunha S.I., Pardali E., Thorikay M., et al. Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. J Exp Med 2010, 207(1):85-100.
58. Shephard P., Martin G., Smola-Hess S., et al. Myofibroblast differentiation is induced in keratinocyte-fibroblast co-cultures and is antagonistically regulated by endogenous transforming growth factor-beta and interleukin-1. Am J Pathol 2004, 164(6):2055-2066.
59. Chen W., Jin W., Hardegen N., et al. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003, 198(12):1875-1886.
60. Huber S., Schramm C., Lehr H.A., et al. Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J Immunol 2004, 173(11):6526-6531.
61. Malhotra N., Robertson E., Kang J. SMAD2 is essential for TGF beta-mediated Th17 cell generation. J Biol Chem 2010, 285(38):29044-29048.
62. Klunker S., Chong M.M., Mantel P.Y., et al. Transcription factors RUNX1 and RUNX3 in the induction and suppressive function of Foxp3+ inducible regulatory T cells. J Exp Med 2009, 206(12):2701-2715.
63. Broide D.H. Immunologic and inflammatory mechanisms that drive asthma progression to remodeling. J Allergy Clin Immunol 2008, 121(3):560-570. [quiz: 571-2].
64. Hackett T.L., Warner S.M., Stefanowicz D., et al. Induction of epithelial-mesenchymal transition in primary airway epithelial cells from patients with asthma by transforming growth factor-beta1. Am J Respir Crit Care Med 2009, 180(2):122-133.
65. Le A.V., Cho J.Y., Miller M., et al. Inhibition of allergen-induced airway remodeling in Smad 3-deficient mice. J Immunol 2007, 178(11):7310-7316.
66. McMillan S.J., Xanthou G., Lloyd C.M. Manipulation of allergen-induced airway remodeling by treatment with anti-TGF-beta antibody: effect on the Smad signaling pathway. J Immunol 2005, 174(9):5774-5780.
67. Coutts A., Chen G., Stephens N., et al. Release of biologically active TGF-beta from airway smooth muscle cells induces autocrine synthesis of collagen. Am J Physiol Lung Cell Mol Physiol 2001, 280(5):L999-L1008.
68. Wynn T.A. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007, 117(3):524-529.
69. Lebman D.A., Edmiston J.S. The role of TGF-beta in growth, differentiation, and maturation of B lymphocytes. Microbes Infect 1999, 1(15):1297-1304.
70. Borsutzky S., Cazac B.B., Roes J., et al. TGF-beta receptor signaling is critical for mucosal IgA responses. J Immunol 2004, 173(5):3305-3309.
71. Presser K., Schwinge D., Wegmann M., et al. Coexpression of TGF-beta1 and IL-10 enables regulatory T cells to completely suppress airway hyperreactivity. J Immunol 2008, 181(11):7751-7758.
72. Akdis C.A., Akdis M., Blesken T., et al. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 1996, 98(7):1676-1683.
73. Jutel M., Akdis C.A. T-cell regulatory mechanisms in specific immunotherapy. Chem Immunol Allergy 2008, 94:158-177.
74. Akdis M. T-cell tolerance to inhaled allergens: mechanisms and therapeutic approaches. Expert Opin Biol Ther 2008, 8(6):769-777.
75. Akdis M., Blaser K., Akdis C.A. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol 2005, 116(5):961-968. [quiz: 969].
76. Aslam A., Chan H., Warrell D.A., et al. Tracking antigen-specific T-cells during clinical tolerance induction in humans. PLoS One 2010, 5(6):e11028.
77. Pereira-Santos M.C., Baptista A.P., Melo A., et al. Expansion of circulating Foxp3+)D25bright CD4+ T cells during specific venom immunotherapy. Clin Exp Allergy 2008, 38(2):291-297.
78. Radulovic S., Jacobson M.R., Durham S.R., et al. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol 2008, 121(6):1467-1472. e1461.
79. Tsai Y.G., Chiou Y.L., Chien J.W., et al. Induction of IL-10+ CD4+ CD25+ regulatory T cells with decreased NF-kappaB expression during immunotherapy. Pediatr Allergy Immunol 2009, 21(1 Pt 2):e166-e173.
80. Boudousquie C., Pellaton C., Barbier N., et al. CD4+CD25+ T cell depletion impairs tolerance induction in a murine model of asthma. Clin Exp Allergy 2009, 39(9):1415-1426.
81. Mobs C., Slotosch C., Loffler H., et al. Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation. J Immunol 2010, 184(4):2194-2203.
82. Mamessier E., Birnbaum J., Dupuy P., et al. Ultra-rush venom immunotherapy induces differential T cell activation and regulatory patterns according to the severity of allergy. Clin Exp Allergy 2006, 36(6):704-713.
83. Tsai Y.G., Yang K.D., Niu D.M., et al. TLR2 agonists enhance CD8+Foxp3+ regulatory T cells and suppress Th2 immune responses during allergen immunotherapy. J Immunol 2010, 184(12):7229-7237.
84. Nouri-Aria K.T., Wachholz P.A., Francis J.N., et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004, 172(5):3252-3259.
85. Pilette C., Nouri-Aria K.T., Jacobson M.R., et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol 2007, 178(7):4658-4666.
86. Muller U., Akdis C.A., Fricker M., et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998, 101(6 Pt 1):747-754.
87. Haselden B.M., Kay A.B., Larche M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 1999, 189(12):1885-1894.
88. Oldfield W.L., Larche M., Kay A.B. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002, 360(9326):47-53.
89. Tarzi M., Klunker S., Texier C., et al. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy 2006, 36(4):465-474.
90. Pereira E.A., Silva D.A., Cunha-Junior J.P., et al. IgE, IgG1, and IgG4 antibody responses to Blomia tropicalis in atopic patients. Allergy 2005, 60(3):401-406.
91. Zinkernagel R.M., Ehl S., Aichele P., et al. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 1997, 156:199-209.
92. Bilo B.M., Rueff F., Mosbech H., et al. Diagnosis of Hymenoptera venom allergy. Allergy 2005, 60(11):1339-1349.
93. Schroeder H.W., Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol 2010, 125(2 Suppl 2):S41-S52.
94. Aalberse R.C., Stapel S.O., Schuurman J., et al. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009, 39(4):469-477.
95. Uermosi C., Beerli R.R., Bauer M., et al. Mechanisms of allergen-specific desensitization. J Allergy Clin Immunol 2010, 126(2):375-383.
96. Carballido J.M., Carballido-Perrig N., Kagi M.K., et al. T cell epitope specificity in human allergic and nonallergic subjects to bee venom phospholipase A2. J Immunol 1993, 150(8 Pt 1):3582-3591.
97. Lau S., Illi S., Platts-Mills T.A., et al. Longitudinal study on the relationship between cat allergen and endotoxin exposure, sensitization, cat-specific IgG and development of asthma in childhood-report of the German Multicentre Allergy Study (MAS 90). Allergy 2005, 60(6):766-773.
98. Custovic A., Hallam C.L., Simpson B.M., et al. Decreased prevalence of sensitization to cats with high exposure to cat allergen. J Allergy Clin Immunol 2001, 108(4):537-539.
99. Francis J.N., James L.K., Paraskevopoulos G., et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008, 121(5):1120-1125. e1122.
100. Mothes N., Heinzkill M., Drachenberg K.J., et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003, 33(9):1198-1208.
101. Wachholz P.A., Soni N.K., Till S.J., et al. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003, 112(5):915-922.
102. Kepley C.L., Taghavi S., Mackay G., et al. Co-aggregation of FcgammaRII with FcepsilonRI on human mast cells inhibits antigen-induced secretion and involves SHIP-Grb2-Dok complexes. J Biol Chem 2004, 279(34):35139-35149.
103. Cady C.T., Powell M.S., Harbeck R.J., et al. IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIB. Immunol Lett 2010, 130(1-2):57-65.
104. Achatz G., Nitschke L., Lamers M.C. Effect of transmembrane and cytoplasmic domains of IgE on the IgE response. Science 1997, 276(5311):409-411.
105. Van Ree R., Van Leeuwen W.A., Dieges P.H., et al. Measurement of IgE antibodies against purified grass pollen allergens (Lol p 1, 2, 3 and 5) during immunotherapy. Clin Exp Allergy 1997, 27(1):68-74.
106. Gleich G.J., Zimmermann E.M., Henderson L.L., et al. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol 1982, 70(4):261-271.
107. Keskin O., Tuncer A., Adalioglu G., et al. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis. Pediatr Allergy Immunol 2006, 17(6):396-407.
108. Di Lorenzo G., Mansueto P., Pacor M.L., et al. Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy. J Allergy Clin Immunol 2009, 123(5):1103-1110. e1101-4.
109. Meiler F., Klunker S., Zimmermann M., et al. Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors. Allergy 2008, 63(11):1455-1463.
110. Dugas-Breit S., Przybilla B., Dugas M., et al. Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy. Clin Exp Allergy 2010, 40(4):643-649.
111. Gri G., Piconese S., Frossi B., et al. CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity 2008, 29(5):771-781.
112. Durham S.R., Ying S., Varney V.A., et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996, 97(6):1356-1365.
113. Wilson D.R., Irani A.M., Walker S.M., et al. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy 2001, 31(11):1705-1713.
114. Wurtzen P.A., Lund G., Lund K., et al. A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation. Clin Exp Allergy 2008, 38(8):1290-1301.
115. Nouri-Aria K.T., Pilette C., Jacobson M.R., et al. IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy. J Allergy Clin Immunol 2005, 116(1):73-79.
116. Wilson D.R., Nouri-Aria K.T., Walker S.M., et al. Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. J Allergy Clin Immunol 2001, 107(6):971-976.
117. Schandene L., Alonso-Vega C., Willems F., et al. B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10. J Immunol 1994, 152(9):4368-4374.
118. Rak S., Hakanson L., Venge P. Immunotherapy abrogates the generation of eosinophil and neutrophil chemotactic activity during pollen season. J Allergy Clin Immunol 1990, 86(5):706-713.
119. Plewako H., Holmberg K., Oancea I., et al. A follow-up study of immunotherapy-treated birch-allergic patients: effect on the expression of chemokines in the nasal mucosa. Clin Exp Allergy 2008, 38(7):1124-1131.
120. Zhao C.Q., Li T.L., He S.H., et al. Specific immunotherapy suppresses Th2 responses via modulating TIM1/TIM4 interaction on dendritic cells. Allergy 2010, 65(8):986-995.
121. Rak S., Lowhagen O., Venge P. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol 1988, 82(3 Pt 1):470-480.
122. Wing K., Larsson P., Sandstrom K., et al. CD4+ CD25+ FOXP3+ regulatory T cells from human thymus and cord blood suppress antigen-specific T cell responses. Immunology 2005, 115(4):516-525.
123. Cottrez F., Hurst S.D., Coffman R.L., et al. T regulatory cells 1 inhibit a Th2-specific response in vivo. J Immunol 2000, 165(9):4848-4853.
124. Chen Y., Kuchroo V.K., Inobe J., et al. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994, 265(5176):1237-1240.
125. Clark R.A., Huang S.J., Murphy G.F., et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med 2008, 205(10):2221-2234.
126. Lewkowich I.P., Herman N.S., Schleifer K.W., et al. CD4+CD25+ T cells protect against experimentally induced asthma and alter pulmonary dendritic cell phenotype and function. J Exp Med 2005, 202(11):1549-1561.
127. Bellinghausen I., Konig B., Bottcher I., et al. Inhibition of human allergic T-helper type 2 immune responses by induced regulatory T cells requires the combination of interleukin-10-treated dendritic cells and transforming growth factor-beta for their induction. Clin Exp Allergy 2006, 36(12):1546-1555.
128. Jaffar Z., Ferrini M.E., Girtsman T.A., et al. Antigen-specific Treg regulate Th17-mediated lung neutrophilic inflammation, B-cell recruitment and polymeric IgA and IgM levels in the airways. Eur J Immunol 2009, 39(12):3307-3314.
129. Kitani A., Fuss I., Nakamura K., et al. Transforming growth factor (TGF)-beta1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-beta1-mediated fibrosis. J Exp Med 2003, 198(8):1179-1188.
130. Trautmann A., Schmid-Grendelmeier P., Kruger K., et al. T cells and eosinophils cooperate in the induction of bronchial epithelial cell apoptosis in asthma. J Allergy Clin Immunol 2002, 109(2):329-337.